O-dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes

Journal of Pharmacology and Experimental Therapeutics

Volumn 300, Issue 1, 2002, Pages 105-111

  Liu, Zhao Qian ^a   Zhu, Bing ^a   Tan, Yun Fu ^b   Tan, Zhi Rong ^b   Wang, Lian Sheng ^b   Huang, Song Lin ^b   Shu, Yan ^a,b   Zhou, Hong Hao ^a  

^a Central South University   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DRUG METABOLITE; FLUOXETINE; MEPHENYTOIN; MIDAZOLAM; OMEPRAZOLE; PARA TRIFLUOROMETHYLPHENOL; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION KINETICS; CONCENTRATION RESPONSE; DEALKYLATION; DRUG METABOLISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; LIVER METABOLISM; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; MUTATION; PRIORITY JOURNAL;

ALGORITHMS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, GAS; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; DNA, COMPLEMENTARY; ELECTROCHEMISTRY; ENZYME INHIBITORS; FLUOXETINE; GENE DOSAGE; GENOTYPE; HUMANS; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; RECOMBINANT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 0036138239     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.300.1.105     Document Type: Article

References (29)

1. Clinical pharmacokinetics of fluoxetine
2. Hydroxylation polymorphism of debrisoquine and mephenytoin in European populations
3. Diazepam metabolism by human liver microsomes is mediated by S-mephenytoin hydroxylase and CYP3A isoforms
4. Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography probe of CYP3A
5. Genetic analysis of the S-mephenytoin polyrnorphism in a Chinese population
6. Differential selectivity of cytochrome P450 inhibitors against probe substrate in human and rat liver microsomes
7. The induction effect of rifampicin on activity of mephenytoin 4′-hydroxylase related to m1 mutation of CYP2C19 and gene dose
8. Fluoxetine, a selective inhibitor of serotonin uptake
9. Inhibition by omeprazole of proguanil metabolism: Mechanism of the interaction in vitro and prediction of in vivo results from in vitro experiments
10. Fluoxetine
11. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrissoquin
12. Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype
13. Pharmacokinetics of selective serotonin reuptake inhibitors
14. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms
15. Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in healthy subjects
16. Effect of the CYP2C19 genotype and 2C9 on fluoxetine N-demethylation in human liver microsomes
17. Protein measurement with Folin phenol reagent
18. Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes
19. Inactivation of cytochrome P450 by a traleandomyein metabolite: Protective role of ghitathione
20. Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects
21. Enzyme kinetic modeling as a tool to analyse the behavior of cytochrome P450 catalyzed reaction: Application to amitriptyline, N-demethylation
22. 5-Hydroxylation of omeprazole by human liver microsomal fraction from Chinese populations related to CYP2C19 gene dose and individual ethnicity
23. Determination of ρ-trifluoxetineoromethylphenol, a metabolite of fluoxetine, in tissues and body fluoxetineids using an electron-capture gas chromatographic procedure
24. Drug metabolism in human liver in vitro: Establishment of a human liver bank
25. Human cytochromes mediating N-demethylation of fluoxetine in vitro
26. Genetic polymorphism of S-mephenytoin hydroxylation
27. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele
28. High-performance liquid chromatographic determination of urinary 4′-hydroxymephenytoin, a metabolic marker for the hepatic enzyme CYP2C19, in human
29. Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes